Positional Therapy as Effective at Normalizing Sleep Apnea in Males as Compared to Female Patients with Positional OSA

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Sleep Specialists, LLC, a medical device company specializing in sleep therapy, announced that their FDA cleared Zzoma Positional Device was used in a clinical trial examining the influence of gender on the effectiveness of positional therapy in the treatment of patients with positional obstructive sleep apnea (OSA).   (Results were presented at the Annual Meeting of the Associated Professional Sleep Societies in Boston Massachusetts).

The new study was conducted out of Temple University in Philadelphia and included patients previously diagnosed with positional sleep apnea.  Following their baseline polysomnography (PSG), all patients underwent a treatment night PSG using the Zzoma Positional Device. There were three major findings. First, baseline characteristics and disease severity are similar in male as compared to female patients with positional OSA. Second, the use of Zzoma resulted in a similar relative change and normalization of AHI in males as compared to female patients. Third, sleep quality and nocturnal oxygenation remained stable in both male and female patients with Zzoma. The findings concluded that positional therapy, as treatment, appears to be equally effective at normalizing sleep disordered breathing in male as compared to female patients diagnosed with positional OSA.

Zzoma is a device worn around the upper torso that keeps patients asleep on their sides by preventing supine or “on-the-back” sleeping. Clinicians may prescribe Zzoma as a first line therapy or as an alternative for patients who cannot tolerate oral appliances or Continuous Positive Airway Pressure (CPAP) therapy.

“For a very long time we questioned how our female patients sleep compared to our male,” says Sila Yesilsoy, COO of Sleep Specialists, LLC. “The new study confirmed that Zzoma is an appropriate solution for both genders and we are happy to report that.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.